Open AccessProprotein Convertase Subtilisin Kexin Type 9 Inhibition for Autosomal Recessive Hypercholesterolemia—Brief Report
Author(s) -
Aurélie Thedrez,
Barbara Sjouke,
Maxime Passard,
Simon Prampart-Fauvet,
Alexis F. Guédon,
Mikaël Croyal,
Geesje M. DallingaThie,
Jorge Peter,
Dirk Blom,
M. Ciccarese,
Angelo B. Cefalù,
Livia Pisciotta,
Raúl D. Santos,
Maurizio Averna,
Frederick J. Raal,
Paolo Pintus,
Maria Laura Cossu,
Kees Hovingh,
Gilles Lambert
Publication year - 2016
Publication title -
arteriosclerosis thrombosis and vascular biology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.007
H-Index - 270
eISSN - 1524-4636
pISSN - 1079-5642
DOI - 10.1161/atvbaha.116.307493
Subject(s) - kexin , proprotein convertase , subtilisin , pcsk9 , familial hypercholesterolemia , medicine , genetics , endocrinology , ldl receptor , cholesterol , biology , biochemistry , lipoprotein , enzyme
Proprotein convertase subtilisin kexin type 9 (PCSK9) inhibitors lower low-density lipoprotein (LDL) cholesterol in the vast majority of patients with autosomal dominant familial hypercholesterolemia. Will PCSK9 inhibition with monoclonal antibodies, in particular alirocumab, be of therapeutic value for patients with autosomal recessive hypercholesterolemia (ARH)?
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom